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Background:
In health, the hormones amylin and glucagon-like peptide-1 (GLP-1) slow gastric emptying (GE) and modulate glycaemia. The aims of this study were to determine amylin and GLP-1 concentrations in the critically ill and their relationship with GE, glucose absorption and glycaemia.
Methods:
In fasted critically ill and healthy subjects (n=26 and 23 respectively) liquid nutrient, containing 100mg 13 C-sodium octanoate and 3g 3-O-methlyglucose (3-OMG), was administered via a nasogastric tube. Amylin, GLP-1, glucose and 3-OMG concentrations were measured in blood samples taken during fasting, and 30 and 60min
after the 'meal'. Breath samples were taken to determine GE (Gastric Emptying Coefficient; GEC). Intolerance to intragastric feeding was defined as a gastric residual volume of ≥250ml and/or vomiting in the 24hours prior to the study.
Results:
Although GE was slower [GEC critically ill: 2.8±0. 
INTRODUCTION
In the critically ill, markedly delayed gastric emptying occurs frequently, which impairs delivery of intragastric nutrition 1, 2 . The pathophysiology of delayed gastric emptying in the critically ill is multi-factorial but reflects, at least in part, a heightened feedback response to the presence of nutrients in the small intestine 3 . In health, hormones secreted from the stomach and small intestine play a pivotal role in the regulation of gastric emptying [4] [5] [6] [7] . For example, cholecystokinin (CCK) and peptide YY (PYY) potently slow gastric emptying, while ghrelin may accelerate it 8 . Our group has reported that fasting and postprandial concentrations of CCK and PYY are elevated in the critically ill, particularly in patients intolerant to intragastric feed 4 . Conversely, the rate of gastric emptying is a determinant of CCK and PYY secretion in the critically ill, as it is in health 5, 9, 10 . Hence, there is evidence of disordered gastrointestinal hormone secretion in the critically ill, which may contribute to delayed gastric emptying.
Amylin is a 37-amino acid polypeptide co-secreted with insulin 11 . In humans, exogenous administration of amylin and the amylin analogue, pramlintide, slows gastric emptying substantially 11 . Furthermore, at least in animal models, amylin appears to be a more potent physiological regulator of gastric emptying than other enterogastrones, including CCK and glucagon-like peptide-1 (GLP-1) 12 . Using gastric residual volumes (GRVs) to determine tolerance to intragastric feed, Mayer and colleagues reported that fasting plasma amylin concentrations were much higher in critically ill children who were intolerant of intragastric feed, when compared to the feed-tolerant 13 , suggesting that endogenous amylin may contribute to slow gastric emptying in the critically ill.
However, there is no information about fasting or nutrient stimulated amylin concentrations in adult critically ill patients. In health and diabetes, there is a complex relationship between upper gastrointestinal function and glycaemic control, such that postprandial glycaemia is both a determinant of, and determined by, gastric emptying 17, 18 . Pre-prandial blood glucose concentrations influence gastric emptying in the critically ill, as is the case in diabetes 17 , while glucose absorption is reduced in these patients compared to health and is dependent on the rate of gastric emptying 19 . Glycaemic control appears to be a pivotal determinant of outcome in the critically ill, with marked hyperglycaemia and hypoglycaemia associated with adverse outcomes including increased mortality and hospital length of stay 20, 21 . However, the relationship between endogenous secretion of GLP-1 and glycaemia in the critically ill is poorly defined 22 .
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The primary objectives of this study were to quantify fasting and postprandial concentrations of amylin and GLP-1 in critically ill adult patients, and to determine whether there is a relationship between these concentrations and the rate of gastric emptying. As gastric emptying affects postprandial blood glucose concentrations which are, in turn, affected by small intestinal glucose absorption, secondary objectives were to quantify blood glucose and glucose absorption.
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METHODS
Subjects
Critically ill patients were eligible for inclusion if aged ≥ 17 years, mechanically ventilated and receiving enteral nutrition. Exclusion criteria included pregnancy, preexisting diabetes and previous surgery on the oesophagus, stomach or duodenum. In patients receiving an insulin infusion (Actrapid; Novo-Nordisk, Denmark), this was ceased 3 hours prior to the commencement of the study. Healthy subjects were used as a comparator. In this group, exclusion criteria included pregnancy or breastfeeding, 
Study Protocol
Subjects were fasted for at least six hours. Following this a fasting blood sample, was obtained and a nutrient liquid test 'meal' of 100 ml Ensure® (Abbott, Victoria, Australia) (64% carbohydrate, 21% lipid, 13% protein, 1.06 kcal/ml) including in critically ill patients 23 .This technique allowed reliable filling of Exetainer (Labco Limited, Buckinghamshire, UK) for measurement of exhaled 13 CO 2 . In healthy subjects, subjects exhaled completely through a straw into the Exetainer. 
Measurements
Gastric emptying
Breath samples were analysed to determine the percentage of 13 C recovered per hour, plotted over time. The area under the recovery curve was used to calculate the gastric emptying coefficient (GEC), which is a global index of the gastric emptying rate that accounts for the rate of appearance and disappearance of tracer in the breath. Greater GEC values indicate the emptying rate is more rapid 23 .
Measurement of blood glucose, plasma amylin and GLP-1 concentrations and glucose absorption
Blood glucose was measured at the bedside with a portable glucometer (Medisense Optimum, Abbott, IL, USA). Plasma total amylin was measured using the Milliplex kit,
with an assay sensitivity of 13 pg/mL, and CVs were <5 % within, and <8 % between, assays. Plasma active GLP-1 was measured using an enzyme-linked immunosorbent assay (ELISA) (Epitope Diagnostics, CA, USA). The assay sensitivity and intra and inter run CV were 0.4pmol/l, and <4 % and <6 % respectively. Serum 3-OMG was used as an index of glucose absorption, measured using liquid chromatography/mass spectroscopy, with an assay sensitivity of 0.0103 mmol/l. 3-OMG is a monosaccharide absorbed from the small intestine via the same transporters as glucose, however is not metabolised, providing an accurate measure of glucose absorption 24, 25 .
Statistical Analysis
Data are presented as mean ± SD or median (range) as appropriate. Depending on data distribution, within-subject comparisons were made using Student's t-test or Wilcoxon
Signed Ranks tests and between-subject comparisons using Mann-Whitney U tests.
Relationships were evaluated using Spearman correlation. The null hypothesis was rejected at a P value ≤0.05. Statistical analyses were performed using SPSS (Version
17.0; SPSS, IL, USA).
Based on the study by Mayer and colleagues 13 it was decided, a priori to classify patients as tolerant or intolerant to intragastric feed and perform subgroup analysis.
Intolerance to intragastric feed was defined as a GRV of ≥250 mL and/or vomiting during feeding within the 24 hours prior to the study 26 . One patient had not commenced enteral feeding prior to the study and, therefore, feed tolerance could not be classified.
This patient was omitted from sub group analysis. As blood glucose concentrations were predictably different at baseline between critically ill patients and healthy subjects, these data are reported as change from baseline. The incremental area under the curve (iAUC) for blood glucose and area under the curve (AUC) for serum 3-OMG concentrations after the meal were calculated using the trapezoidal rule. 
RESULTS
Subjects
Gastric Emptying
When compared to health, critical illness was associated with slower gastric emptying 
Plasma amylin concentrations
During fasting, amylin concentrations were similar in critically ill and healthy subjects 
Blood glucose concentrations
Fasting blood glucose concentrations were greater in critical illness than health 
Glucose absorption
Glucose absorption was also reduced in critical illness compared to health 
DISCUSSION
This study was performed primarily to gain insights into whether elevated concentrations of amylin and GLP-1 have a potential role in the delayed gastric emptying that occurs frequently in adult critically ill patients. In the cohort studied, gastric emptying was much slower than in health, as would be predicted. Novel findings are that in the critically ill, fasting GLP-1 concentrations were greater than in healthy subjects, particularly in patients intolerant to intragastric feed, while fasting amylin concentrations were comparable between critical illness and health. However, the rate of gastric emptying was not related to fasting concentrations of either amylin or GLP-1, suggesting that they are not major determinants of gastric emptying in this group.
Consistent with previous findings, the rate of glucose absorption was reduced 25 and fasting blood glucose concentrations greater in critically ill patients when compared to health 25 .
The observation that amylin concentrations did not appear to be a determinant of feed tolerance in this adult cohort differs from a previous report in critically ill children, in which increased serum amylin concentrations were associated with delayed gastric emptying 13 . However the latter study may have had methodological limitations including a small sample size and a heterogeneous cohort, including a wide age range 13 .
While our cohort was not large, a substantial difference in amylin levels would appear unlikely to be found with even greater numbers. It is also possible that different factors influence gastric motility in critically ill children and adults.
Potential limitations of the current study should be recognised. Metabolism and/or excretion of hormones is often reduced in the critically ill -especially in patients with three-fold greater than in patients tolerating intragastric feed and almost five-fold the concentrations observed in health. However, the radioisotope breath test used to measure gastric emptying, while validated in the critical care, is less precise than the 'gold-standard' of scintigraphy 29 . In addition, the assigning of patients to a feed tolerance status by dichotomizing on the basis of GRVs, may have inaccuracies 30 .
However, the use of a GRV of ≥250ml as an indication of feed intolerance is a clinical measure used by the centre at which the study was performed to indicate the requirement for therapies to treat failed intragastric feeding i.e. prokinetic therapy or small intestinal feeding catheters, and hence is of clinical significance to critically ill patients.
The cohort studied was a heterogeneous sample of critically ill patients, and other nonhormonal factors may have contributed to delayed gastric emptying, such as opiate administration 31 . Moreover, we have reported that pharmacological doses of GLP-1, the peptide that profoundly slows gastric emptying in health, may not have an effect when gastric emptying is already delayed 14 . For these reasons we cannot exclude the possibility that GLP-1 may play a role in the regulation of gastric emptying in the critically ill, with an effect on glucose absorption and postprandial glycaemia. We have previously demonstrated, using the specific GLP-1 antagonist exendin 9-39 amide, that endogenous GLP-1 slows GE in health, thereby attenuating postprandial glycaemia 6 .
However, there are substantial logistical difficulties with undertaking a study using exendin 9-39 in the critically ill and there is no currently available amylin antagonist.
Accordingly, although the current study may have failed to show an effect of GLP-1 and/or amylin on gastric emptying because of type II error, we suggest that this study is the best currently available evidence.
In conclusion, neither the endogenous secretion of amylin, nor GLP-1, appears to be a major determinant of gastric emptying in the critically ill.
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